Nyxoah S.A.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $160.1M
- Price
- $1.60
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.44%
- Volume
- 164.1K
About
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Quick stats
Shares outstanding100.1M
Computed float20.5M
Float / shares20.5%
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001857190
Websitehttps://www.nyxoah.com
AI Summary
AI-generated1/50
majorbullishearnings
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Nyxoah reported Q2 2026 net revenue of €7.7 million, representing 21% sequential growth and a significant increase from €1.3 million in the prior year, driven by U.S. commercial execution.
Operational metrics showed strong momentum with 89 new accounts activated in the quarter, bringing the total to 180, and a 77% increase in patients actively under prior authorization.
The company secured $110 million in aggregate financing during the quarter, ending with €97.8 million in cash, and reaffirmed full-year revenue guidance of €36 million to €40 million.
Red flags
- Gross margin decline to 60% in Q2 2026 from 63% in Q2 2025 due to higher mix of U.S. revenue and production yield issues in Q1